For Clinics

The Case That Psychedelics Sometimes Make Thinking Less Flexible

Cognitive flexibility is the standard explanation for how psychedelics work. A new review argues the acute effect may sometimes run the other way.

New Mexico Just Opened Its First Psilocybin Permits. The One Clinicians Need Is Still Coming

New Mexico began accepting psilocybin producer applications on August 17. The clinician permit has not opened, and the end of 2026 target looks unlikely.

Two Infusions a Year, Two Years of Relief: Inside a 92 Patient Fibromyalgia Ketamine Study

A Winston-Salem clinic tracked 92 fibromyalgia patients on high dose ketamine for two years. The dosing model looks nothing like standard practice.

As Psychedelic Care Gets Leaner, the Integration Work Moves Home. Our Data Says Home Is a Coin Flip

A new Canadian Journal of Psychiatry paper argues leaner psychedelic protocols displace integration work onto patients’ families. HealingMaps survey data shows those households split evenly.

A Federal Report Just Told States to Prepare for Psychedelic Approval. Ketamine Clinics Are the Template

SAMHSA told states to build the budget, licensing, and oversight machinery for psychedelic therapy before the FDA approves anything. Ketamine is not named once.

Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster

Lilly paid up to $3.8 billion for a compound whose selling point is a two hour clinic visit. Session length, not efficacy, is now the axis that separates psychedelic programs.

Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months

A JAMA Network Open study followed 346 people through Oregon's licensed psilocybin program. The adverse events showed up long after the state stops looking.

The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too

The VA began enrolling 240 veterans in a phase 3 psilocybin trial on August 3. There is no placebo arm, and that changes what the study can prove.

Three Infusions in Twelve Weeks: A Toronto Pain Trial Ran a Very Different Protocol

A Toronto trial paired ketamine with structured therapy for chronic nerve pain. It used three infusions over twelve weeks, not six over three.

An Oral LSD Tablet Has Now Cleared Phase 3 Twice This Year. Here Is What Comes Next

Editor’s note (September 16, 2026): DT120 has since cleared a third Phase 3 trial. We covered the Panorama results and the low-dose arm designed to address unblinding. An oral LSD tablet has now cleared phase 3 twice in a single year. Definium Therapeutics reported that DT120 ODT met its primary endpoint in generalized anxiety disorder, […]